Target Professions: DO, MD, Nurse Practitioner, Physician Associate/Assistant
Target Specialties: Allergy and Immunology, Dermatology, Pediatric Dermatology
Credits Available: 7.25 AMA PRA Category 1 Credit™, ABIM MOC

Chronic spontaneous urticaria (CSU) is a common, chronic inflammatory skin disease significantly impacting patients' quality of life and associated with substantial healthcare costs. While effective management strategies are available, many patients experience diagnostic delays and suboptimal treatment, underscoring an urgent need for refined diagnostic strategies, better implementation of current therapies, and improved clinician awareness of emerging treatments. This educational initiative will enhance management and ultimately improve the outcomes for patients with CSU.


CME/CE Accreditation Information

Itinerary

CSU Fundamentals

Baseline Assessment

Answer the following questions to assess your knowledge on CSU management.

Diagnosis of CSU

This module covers CSU diagnosis guidelines, including differentiation from other disorders and appropriate use of laboratory tests and imaging. This module also addresses CSU endotypes and biomarkers for individualizing diagnostic strategies and predicting therapy response.

Current Treatment Strategies for CSU

This module explores current CSU treatment algorithms, covering appropriate use of guideline-recommended therapies such as second-generation antihistamines and omalizumab. The module also addresses special populations, patient-centered care, and shared decision-making.

Emerging Treatment Strategies for CSU

This module explores novel CSU therapies, including BTK and IL-4/13 inhibitors, and mast cell-targeting agents. We will assess their efficacy and safety to determine their role in addressing unmet needs for patients with uncontrolled CSU.

Final Assessment

Now that you have reviewed the self-study modules, answer the following questions to assess your knowledge of CSU management.

Patient Case – SK, a 38-year-old woman with CSU

This activity features a 38-year-old woman with CSU refractory to antihistamines. The patient case activity highlights the challenges of diagnostic delays, treatment escalation, and factors influencing therapeutic choices.

Live Group Discussion 1

Review of CSU Fundamentals and Patient Case

Latest CSU Developments

Live Group Discussion 2

CSU Highlights from Fall Clinical Dermatology Conference and ACAAI Annual Scientific Meeting (November/December 2025)

Live Group Discussion 3

CSU Highlights from the AAAAI Annual Meeting (March 2026)

Live Group Discussion 4

CSU Highlights from the AAD Annual Meeting (April 2026)

Your Action Plan in CSU

In light of the information reviewed and discussed during this program, please share an action plan that you will implement to improve the diagnosis and management for your patients with CSU.

Interested in becoming a Group Leader?

Requirements:
Group Leaders are required to be regional experts in the management of CSU. Preference will be given to clinicians attending one or more of the key allergy / dermatology conferences. Apply Now

You cannot sign up as a Group Member because there are no groups available or because you are already signed up.